CHARLES M BALCH to Adolescent
This is a "connection" page, showing publications CHARLES M BALCH has written about Adolescent.
Connection Strength
0.091
-
Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007 Apr 10; 25(11):1363-8.
Score: 0.017
-
Melanoma in children: heightened awareness of an uncommon but often curable malignancy. Pediatrics. 2005 Mar; 115(3):802-3.
Score: 0.014
-
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
Score: 0.011
-
Prognostic implications of DNA index in patients with stage III cutaneous melanoma. Am J Surg. 1993 Dec; 166(6):648-52; discussion 652-3.
Score: 0.007
-
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993 Sep; 218(3):262-7; discussion 267-9.
Score: 0.007
-
Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg. 1992 Nov; 164(5):462-5; discussion 465-6.
Score: 0.006
-
Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989 Sep; 124(9):1051-5.
Score: 0.005
-
Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009 Apr 10; 27(11):1857-63.
Score: 0.005
-
An integrated tree-based classification approach to prognostic grouping with application to localized melanoma patients. J Biopharm Stat. 2007; 17(3):445-60.
Score: 0.004
-
Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983 Jun 01; 51(11):2152-6.
Score: 0.003
-
A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer. 1982 Mar 15; 49(6):1079-84.
Score: 0.003
-
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998 Jul; 187(1):69-77; discussion 77-9.
Score: 0.002
-
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
Score: 0.002
-
Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996 Sep; 3(5):446-52.
Score: 0.002
-
Kidney transplantation in patients with end stage congenital renal disease. Report of eighteen cases and review of the Organ Transplant Registry. Am J Surg. 1975 Sep; 130(3):303-8.
Score: 0.002
-
A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). Am Surg. 1986 Mar; 52(3):148-51.
Score: 0.001